Document:

exv10w57

Exhibit 10.57

PHARMACEUTICAL COMPANY

March 4, 2008

Lisa Koch-Hulle

[Address]

Re:       Promotion to VP, Regulatory Affairs & Project Management

Dear Lisa:

We are pleased to confirm your promotion to the position of Vice President, Regulatory Affairs &
Project Management, reporting to Michael Tansey, EVP & CMO, Development. The effective date of this
promotion was February 5, 2007. This offer and your employment relationship will be subject to the
terms and conditions of this letter.

In this position, your new salary will be $164,150.00 annualized, less applicable withholdings,
paid in accordance with Company’s normal payroll practices. Future adjustments in compensation, if
any, will be made by Company in its sole and absolute discretion. This position is an exempt
position, which means you are paid for the job and not by the hour. Accordingly, you will not
receive overtime pay if you work more than 8 hours in a work day or 40 hours in a workweek.

You will remain eligible for all fringe benefits available to other “full-time” Company employees,
including medical, dental insurance, 401k plan, in accordance with Company’s benefit plans. Company
reserves the right to change or eliminate these benefits on a prospective basis at any time.

As part of this promotion, the Company’s Board of Directors’ has granted options to purchase 12,500
shares of Company’s common stock in accordance with Company’s 2004 Equity Incentive Plan (the
“Plan”) and related option documents.

You will also continue to be eligible to participate in the management incentive compensation plan
that has been established by Company during your employment, with a target bonus of up to 30% of
your base salary. The bonus will be determined by the achievement of goals tied to your position
and the achievement of overall corporate goals and is subject to approval by the Company’s Board of
Directors.

Your employment with Company continues to be “at-will.” This means your employment is not for any
specific period of time and can be terminated by you at any time for any reason. Likewise, Company
may terminate the employment relationship at any time, with or without cause or advance notice. In
addition, Company reserves the right to modify your position or duties to meet business needs and
to use discretion in deciding on appropriate discipline. Any change to the at-will employment
relationship must be by a specific, written agreement signed by you and Company’s President.

6455 Nancy Ridge Drive • San Diego, California 92121 • Phone 858-452-6600 • Fax 858-554-0234

www.ljpc.com

 

 

Lisa Koch-Hulle

Page 2

If your employment is terminated by Company for other than Cause, you will receive a severance
amount equal to 6 months of your then current base salary, provided you sign a separation
agreement in a form acceptable to Company, including a complete release of claims. For purposes of
this offer letter, “Cause” shall mean your employment is terminated for dishonesty, misconduct,
failure or inability to perform your job duties (with reasonable accommodation, if required by
law), or other conduct that has a material adverse effect on the name or public image of Company.

This letter constitutes the entire agreement between you and Company relating to this subject
matter and supersedes all prior or contemporaneous agreements, understandings, negotiations or
representations, whether oral or written, express or implied, on this subject. This letter may not
be modified or amended except by a specific, written agreement signed by you and Company’s
President.

Lisa, congratulations on your promotion and we wish you continued success in this new opportunity.
If you have any questions, please feel free to call me at 858-646-6605.

Sincerely,

	 	 	 
	/s/ Vickie Motte
 

Vickie Motte

	 	 
	Sr. Director, Human Resources
	 	 
	La Jolla Pharmaceutical Company
	 	 

*       *       *

I have read this offer letter in its entirety and agree to the terms and conditions of employment.
I understand and agree that my employment with Company is at-will.

	 	 	 	 	 
	Dated
4 Mar 08

	 	/s/ Lisa Koch-Hulle
 

Lisa Koch-Hulle
	 	 

6455 Nancy Ridge Drive • San Diego,California 92121 • Phone 858-452-6600 • Fax 858-625-0155

www.ljpc.comexv10w58

Exhibit 10.58

AMENDMENT TO EXECUTIVE

EMPLOYMENT AGREEMENT

     This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”), dated as of December 24, 2008,
is between La Jolla Pharmaceutical Company, a Delaware corporation, with its principal place of
business located at 6455 Nancy Ridge Drive, San Diego, California 92121 (the “Employer”),
and Gail Sloan (the “Employee”).

     WHEREAS, the Employee is currently employed as Vice President, Finance of the Employer under an
Executive Employment Agreement dated as of February 23, 2006 (the “Agreement”); and

     WHEREAS, the Board of Directors (the “Board”) of Employer, pursuant to Board approval on
December 24,  2008, has authorized changes to employment documentation in order to conform to
the provisions of IRC Section 409A relating to nonqualified deferred compensation arrangements and
the parties hereto consider it appropriate that the Agreement be amended to reflect such
arrangements;

     NOW, THEREFORE, in consideration of the mutual covenants herein contained, the Employer and the
Employee agree to the following amendment to the Agreement. Capitalized terms used in this
Amendment that are not otherwise defined shall have the same meanings as in the Agreement, provided
that the terms “Employer” and the “Company” shall be used interchangeably in the Agreement and this
Amendment.

	 	1.	 	Section 2(a)(A) of the Agreement is hereby deleted in its entirety and replaced with the
following:

“Termination; Severance. Employee will be entitled to receive from the Company an amount in
severance equal to one year of Employee’s then-current base salary (the “Severance Amount”). The
Severance Amount will be paid in a lump sum on the first payroll date that is 30 days after the
date of Employee’s termination of service, provided that Employee has executed and delivered to the
Company a mutual release, within 21 days of her date of termination from service, in form and
substance satisfactory to the Company, of all claims arising in connection with Employee’s
employment with the Company and termination thereof and has not revoked said release;”

 

 

	 	2.	 	Section 2(a)(B) of the Agreement is hereby deleted in its entirety and replaced with the
following:

“In addition, Company will pay the monthly premiums for group health care continuation coverage for
Employee and Employee’s eligible dependents pursuant to the Consolidated Omnibus Budget
Reconciliation Act of 1986 (“COBRA”) for 12 full calendar months following termination,
provided Employee elects to continue and remains eligible for such benefits during this
period.”

	 	3.	 	Section 3(a) of the Agreement is hereby deleted in its entirety and replaced with the
following:

"(a) Notwithstanding any provision of this Agreement to the contrary, if, at the time of Employee’s
termination of employment with the Company, Employee is a “specified employee” as defined in
Section 409A of the Internal Revenue Code (the “Code”), and one or more of the payments or benefits
received or to be received by Employee pursuant to this Agreement or otherwise would constitute
deferred compensation subject to Section 409A, then no such payment will be made under this
Agreement until the earlier of (i) the date which is six months and one day after Employee’s
separation from service or (ii) the date of Employee’s death.”

	 	4.	 	No Other Amendment. Except as otherwise set forth herein, the Agreement shall not be
otherwise amended and remains in full force and effect.

 

 

IN WITNESS WHEREOF, the Employer and Employee have executed this Amendment 1 as of the day set
forth above.

	 	 	 	 	 	 	 
	 	 	LA JOLLA PHARMACEUTICAL COMPANY	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Deirdre Y. Gillespie	 	 
	 

	 	 	 	 

Deirdre Y. Gillespie
	 	 
	 

	 	 	 	President & CEO	 	 
	 
	 	 	 	 	 	 
	 	 	EXECUTIVE	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	/s/ Gail Sloan
 

Gail Sloanexv10w59

Exhibit 10.59

AMENDMENT TO EXECUTIVE OFFICER

EMPLOYMENT AGREEMENT

     This FIRST AMENDMENT TO CHIEF FINANCIAL OFFICER, CHIEF BUSINESS OFFICER AND EXECUTIVE
VICE-PRESIDENT EMPLOYMENT AGREEMENT (“Amendment”), dated as of December 24, 2008, is between
La Jolla Pharmaceutical Company, a Delaware corporation, with its principal place of business
located at 6455 Nancy Ridge Drive, San Diego, California 92121 (the “Employer”), and Niv
Caviar (the “Employee”).

     WHEREAS, the Employee is currently employed as Chief Financial Officer, Chief Business Officer and
Executive Vice President of the Employer under an Executive Employment Agreement dated as of May
10, 2007 (the “Agreement”); and

     WHEREAS, the Board of Directors (the “Board”) of Employer, pursuant to Board approval on
December 24, 2008, has authorized changes to employment documentation in order to conform to the
provisions of IRC Section 409A relating to nonqualified deferred compensation arrangements and the
parties hereto consider it appropriate that the Agreement be amended to reflect such arrangements;

     NOW, THEREFORE, in consideration of the mutual covenants herein contained, the Employer and the
Employee agree to the following amendment to the Agreement. Capitalized terms used in this
Amendment that are not otherwise defined shall have the same meanings as in the Agreement, provided
that the terms “Employer” and the “Company” shall be used interchangeably in the Agreement and this
Amendment.

	 	1.	 	Section 4.3 of the Agreement is hereby deleted in its entirety and replaced with the
following:

     “Annual Bonus. Executive will be eligible to earn an annual bonus based on achievement of
specified performance goals and objectives in accordance with Company’s bonus plan and paid out in
the following year. Executive’s target bonus for calendar year 2007 will be 35% of the Base Salary
prorated for Executive partial year of service based on the Effective Date.”

	 	2.	 	Section 7.2(a) of the Agreement is hereby deleted in its entirety and replaced with the
following:

     “(a) Severance Package. If Executive is terminated without Cause, Executive will receive
a severance payment equivalent to nine months of Executive’s Base Salary then in effect, payable in
installments in accordance with Company’s normal payroll schedule beginning within 30 days after
the date of termination of service provided that the release described in subsection 7.2(b) has
become effective. In addition, Company will pay the monthly premiums for

 

 

group health care continuation coverage for Executive and Executive’s eligible dependents pursuant
to the Consolidated Omnibus Budget Reconciliation Act of 1986 (“COBRA”) for nine months following
termination, provided Executive elects to continue and remains eligible for such benefits
and does not become eligible for health coverage through another employer during this period.
Furthermore, any outstanding options to purchase common stock of Company held by Executive as of
the date of Executive’s termination under this Section 7.2 shall immediately vest and become
exercisable, notwithstanding any contrary terms and provisions of the applicable stock option plan
and related stock option agreements.”

	 	3.	 	Section 7.2(b) of the Agreement is hereby deleted in its entirety and replaced with the
following:

     “(b) Conditions to Receive Severance Package. The Severance Package pursuant to subsection
7.2(a) will be paid, provided Executive meets both of the following conditions: (i)
Executive complies with all surviving provisions of this Agreement as specified in subsection 13.8;
and (ii) Executive executes a full general release within 21 days of the termination of service; in
a form suitable to Company, releasing all claims, known or unknown, that Executive may have against
Company arising out of or any way related to Executive’s employment or termination of employment
with Company.”

	 	4.	 	Section 7.5(b) of the Agreement is hereby amended by adding the following sentence at
the end thereof:
	 
	 	 	 	“The reduction of the amounts payable hereunder, if applicable, shall be made by first reducing the
cash payments pursuant to Section 7.2(a), and in any event shall be made in such a manner so as to
maximize the value of the Severance Package actually paid to the Executive.”
	 
	 	5.	 	No Other Amendment. Except as otherwise set forth herein, the Agreement shall
not be otherwise amended and remains in full force and effect.

 

 

     IN WITNESS WHEREOF, the Employer and Employee have executed this Amendment 1 as of the day set
forth above.

	 	 	 	 	 	 	 
	 	 	LA JOLLA PHARMACEUTICAL COMPANY	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Deirdre Y. Gillespie
 

Deirdre Y. Gillespie
	 	 
	 

	 	 	 	President & CEO	 	 
	 
	 	 	 	 	 	 
	 	 	EXECUTIVE	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	/s/ Niv Caviar
 

Niv Caviar

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]